Dapagliflozin
Dapagliflozin is an oral diabetes medication that blocks SGLT2 in the kidneys to reduce glucose reabsorption, helping to lower blood sugar levels.
An SGLT2 inhibitor that lowers blood sugar by helping the kidneys remove glucose through urine.
Key facts at a glance
- ATC
- A10BK01
- RxNorm
- 1488564
- Generic
- Dapagliflozin
- Class
- atc-a10
- Brands
- Farxiga, Xigduo, Qtern
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 10mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 10mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 10mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
12 groupspregnancy
first trimesteravoid if possible
Discontinue use when pregnancy is detected. Use only if potential benefits justify potential risks to the fetus.
Regular fetal monitoring and assessment of renal function in the fetus
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
Discontinue use when pregnancy is detected. Consider alternative antidiabetic agents.
Regular fetal monitoring, ultrasound for fetal growth
Use with caution and monitor for adverse effects.
pregnancy
third trimesterdiscontinue before third trimester
Do not use in third trimester. Switch to insulin for glycemic control.
Intensive fetal monitoring, assess amniotic fluid volume
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingdiscontinue breastfeeding or discontinue drug
Dapagliflozin is not recommended during breastfeeding. Discontinue nursing or discontinue the drug.
Monitor infant for hypoglycemia and signs of dehydration
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly 65 and olderstart at lowest dose
Use with caution. Start at 5mg once daily. Monitor renal function and for signs of volume depletion.
Regular monitoring of renal function, blood pressure, and hydration status
Use with caution and monitor for adverse effects.
pediatric_age
under 18 yearsnot recommended
Not recommended for use in patients under 18 years of age. Safety and efficacy not established.
N/A - not studied
renal_impairment
mildno adjustment needed
No dosage adjustment required for mild renal impairment (eGFR 60-89).
Monitor renal function periodically
renal_impairment
moderatedose adjustment may be needed
Use with caution in moderate renal impairment (eGFR 30-59). Monitor renal function more frequently.
Regular monitoring of renal function every 3-6 months
Use with caution and monitor for adverse effects.
renal_impairment
severecontraindicated
Not recommended for patients with severe renal impairment (eGFR <30) or ESRD. Discontinue if eGFR falls below 30.
Monitor renal function closely, contraindicated at eGFR <30
Use of this medication in this population requires careful consideration of risks and benefits.
hepatic_impairment
mildno adjustment needed
No dosage adjustment required for mild hepatic impairment.
Routine monitoring
hepatic_impairment
moderateno specific adjustment
Use with caution in moderate hepatic impairment. No specific dose adjustment required.
Monitor for liver function changes
Use with caution and monitor for adverse effects.
hepatic_impairment
severeuse with caution
Use with caution in severe hepatic impairment. Not recommended in severe hepatic impairment due to limited data.
Close monitoring of liver function and clinical status
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
Dapagliflozin (Farxiga) first FDA approved
Drug class
Sodium-glucose co-transporter 2 inhibitor
Common uses
Approved therapeutic indications
Brand names
marketed brand names
Treats type 2 diabetes in adults, often in combination with diet and exercise. May also be prescribed for heart failure or chronic kidney disease in certain patients.
Inhibits SGLT2 (sodium-glucose cotransporter 2) in the proximal renal tubules, blocking reabsorption of filtered glucose and allowing it to be eliminated in urine.
May increase risk of genital yeast infections and urinary tract infections. Not recommended for type 1 diabetes or diabetic ketoacidosis. Patients should stay well hydrated and monitor for signs of infection.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy